Opus Genetics (NASDAQ:IRD) Given New $13.00 Price Target at Wedbush

Key Points

• Wedbush raised Opus Genetics’ price target to $13 from $10 and maintained an “outperform” rating, implying 126.88% potential upside from the prior close. Analysts overall rate the stock “Moderate Buy,” with an average target of $11.92.
• The company reported encouraging early results from its Phase 1/2 BIRD-1 trial: all five low-dose participants showed clinically meaningful visual-function improvements, with no serious adverse events. Management is targeting completion of additional dosing in late 2026 and potential Phase 3 dosing in 2027.
• Opus Genetics remains financially unprofitable, reporting a quarterly loss of $0.14 per share and only $0.76 million in revenue, while insiders sold shares primarily to cover tax withholding obligations. Institutional ownership increased, with several funds establishing new positions during the second quarter.

Opus Genetics (NASDAQ:IRD - Get Free Report) had its price objective upped by equities research analysts at Wedbush from $10.00 to $13.00 in a research note issued on Thursday, Benzinga reports. The brokerage presently has an "outperform" rating on the stock. Wedbush's price target would indicate a potential upside of 126.88% from the stock's previous close.

IRD has been the subject of a number of other reports. Weiss Ratings restated a "sell (d-)" rating on shares of Opus Genetics in a report on Friday, July 17th. Guggenheim assumed coverage on shares of Opus Genetics in a research report on Thursday, June 4th. They issued a "buy" rating and a $16.00 target price on the stock. Leerink Partners started coverage on shares of Opus Genetics in a research note on Thursday, May 21st. They issued an "outperform" rating and a $10.00 price target for the company. TD Cowen assumed coverage on shares of Opus Genetics in a research report on Wednesday, July 29th. They set a "buy" rating for the company. Finally, Royal Bank Of Canada reduced their price objective on Opus Genetics from $10.00 to $9.00 and set an "outperform" rating on the stock in a research note on Friday, August 7th. One research analyst has rated the stock with a Strong Buy rating, fifteen have issued a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average price target of $11.92.

Opus Genetics Trading Up 32.0%

Shares of NASDAQ IRD opened at $5.73 on Thursday. The stock's 50-day moving average is $3.82 and its 200 day moving average is $4.30. The stock has a market cap of $473.58 million, a price-to-earnings ratio of -4.24 and a beta of 0.58. Opus Genetics has a 1-year low of $1.32 and a 1-year high of $7.07.

Opus Genetics (NASDAQ:IRD - Get Free Report) last issued its earnings results on Thursday, August 6th. The company reported ($0.14) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.16) by $0.02. Opus Genetics had a negative return on equity of 338.88% and a negative net margin of 1,091.82%.The business had revenue of $0.76 million during the quarter, compared to analyst estimates of $2.63 million. On average, analysts forecast that Opus Genetics will post -0.99 EPS for the current fiscal year.

Insider Buying and Selling

In related news, CEO George Magrath sold 9,475 shares of the company's stock in a transaction on Thursday, July 23rd. The shares were sold at an average price of $2.95, for a total transaction of $27,951.25. Following the completion of the sale, the chief executive officer directly owned 1,731,869 shares in the company, valued at $5,109,013.55. This represents a 0.54% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CFO Robert E. Gagnon sold 28,000 shares of the firm's stock in a transaction on Thursday, September 3rd. The stock was sold at an average price of $4.54, for a total transaction of $127,120.00. Following the completion of the sale, the chief financial officer directly owned 556,375 shares in the company, valued at approximately $2,525,942.50. This trade represents a 4.79% decrease in their position. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last three months, insiders have sold 57,331 shares of company stock valued at $213,749. Insiders own 11.70% of the company's stock.

Hedge Funds Weigh In On Opus Genetics

Several hedge funds and other institutional investors have recently modified their holdings of the company. Trails Edge Capital Partners LP purchased a new position in Opus Genetics during the 2nd quarter valued at $11,276,434. ADAR1 Capital Management LLC bought a new position in Opus Genetics in the 2nd quarter worth $7,331,000. BlackRock Inc. purchased a new stake in shares of Opus Genetics in the 2nd quarter worth about $12,809,000. Nantahala Capital Management LLC purchased a new stake in shares of Opus Genetics in the 2nd quarter worth about $12,582,185. Finally, AWM Investment Company Inc. purchased a new position in shares of Opus Genetics during the second quarter valued at about $956,000. 14.97% of the stock is owned by institutional investors.

Key Stories Impacting Opus Genetics

Here are the key news stories impacting Opus Genetics this week:

• Positive Sentiment: Opus Genetics reported positive results from the low-dose cohort of its Phase 1/2 BIRD-1 trial. All five participants showed clinically meaningful visual-function improvement, with no serious adverse events or dose-limiting toxicities; improvements in visual acuity were observed in three participants. Opus Genetics Announces Positive Low Dose Cohort 1 Data
• Positive Sentiment: The company said a successful FDA Type C meeting provided alignment on a potential pivotal endpoint involving microperimetry improvement and patient-reported outcomes. Cohort 2 was over-enrolled, with dosing expected to finish in the fourth quarter of 2026 and three-month data targeted for the second quarter of 2027. Opus Genetics Reports Positive OPGx-BEST1 Data
• Positive Sentiment: Analysts raised their valuations and maintained bullish ratings: Wedbush increased its target to $13 from $10, Oppenheimer raised its target to $20 from $10, while BTIG, Chardan and HC Wainwright maintained Buy ratings with targets of $12, $13 and $8, respectively. Wedbush Raises Opus Genetics Price Target
• Positive Sentiment: Unusually heavy call-option buying—4,820 contracts versus typical volume of about 617—signaled increased speculative interest following the clinical update.
• Neutral Sentiment: Management expects cash resources to support operations into 2029, potentially funding several upcoming clinical milestones and reducing near-term financing concerns.
• Negative Sentiment: CFO Robert Gagnon sold 28,000 shares valued at $127,120. The filing said the transaction was made to cover tax withholding tied to vested equity awards, limiting its negative significance, though it remains an insider-sale signal. Opus Genetics CFO Stock Sale

About Opus Genetics

Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. Opus Genetics Inc, formerly known as Ocuphire Pharma Inc, is based in Farmington Hills, Michigan.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.